CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of paroxysmal nocturnal hemoglobinuria.
  
  LEARNING OBJECTIVES

  • Develop a greater understanding of the incidence, pathogenesis and common clinical manifestations of paroxysmal nocturnal hemoglobinuria (PNH), and identify patients with this disease for whom initiation of active therapy is warranted.
  • Understand the means by which C5 complement inhibitors hinder intravascular hemolysis and ameliorate resultant symptoms in patients with PNH, and recall published efficacy and safety data with and practical advantages and disadvantages of the various approved and investigational agents in this class.
  • Evaluate the similarities and differences in the mechanisms of action, methods of administration and propensity for the development of side effects with various available and investigational C5 complement inhibitors.
  • Recognize the clinical implications of breakthrough hemolysis among patients with PNH receiving C5 inhibitor therapy in order to properly identify individuals for whom a change in treatment might be warranted.
  • Appreciate available efficacy and safety findings with proximal complement inhibitors for patients with PNH in order to optimally incorporate these agents into current management algorithms.
  • Recognize adverse events and other practical considerations associated with available and investigational therapies employed for PNH, and develop strategies to minimize toxicities and maximize treatment benefit.
  • Recollect other agents and strategies under evaluation for PNH, and counsel appropriately selected patients about participation in active research protocols.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/PNH2024/CaseRoundtable/Presentation/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jamile M Shammo, MD
  Dr Marjorie C Barnett — Dr Hau C Kwaan Professor
  Professor of Medicine
  Director, Bone Marrow Failure
  Division of Hematology/Oncology
  Northwestern University Feinberg School of Medicine
  Chicago, Illinois
  
  Advisory Committees and Consulting Agreements: Alexion Pharmaceuticals, Apellis, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Novartis, Omeros, Regeneron Pharmaceuticals Inc, Samsung Bioepis, Sanofi, Sobi; Contracted Research: Apellis, Novartis, Protagonist Therapeutics; Data and Safety Monitoring Boards/Committees: Apellis, NS Pharma Inc; Speakers Bureaus: Alexion Pharmaceuticals, Geron Corporation, Sanofi; Stock Options/Stock — Public Company: AbbVie Inc; Nonrelevant Financial Relationship: MJH Life Sciences.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSeraTherapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novartis.
  
  Release date: December 2024
  Expiration date: December 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.